Abstract
Using 31P magnetic resonance spectroscopy, we examined changes in the levels of phosphorus metabolites in the temporal lobes of 13 schizophrenic patients before and 12 weeks after initiating haloperidol treatment. Spectra were obtained from a volume of interest positioned in each temporal lobe. Findings were compared with those in 13 age- and gender-matched healthy subjects. Prior to treatment the patients showed higher levels of phosphodiesters (PDE) in both temporal lobes than healthy subjects. Haloperidol administration significantly reduced the excess of PDE in the left temporal lobe, although the PDE concentration remained somewhat higher bilaterally than in controls. Treatment was associated with a decline in the total symptom score according to the Brief Psychiatric Rating Scale and the score for positive symptoms showed a relatively high correlation with reduction in PDE level in the left temporal lobe. These preliminary results suggest that haloperidol may partially normalize disturbed metabolism or abnormalities in components of membrane phospholipids in the left temporal lobe of untreated schizophrenic patients, paralleling symptom alleviation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association. (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised. Washington DC, American Psychiatric Association
Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Ponto LLB, Hichwa RD . (1997): Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naıuml;ve patients. Lancet 349: 1730–1734
Berman I, Merson A, Sison C, Allan E, Schaefer C, Loberboym M, Losonczy MF . (1996): Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: A pilot study. Psychopharmacol Bull 32: 95–100
Bertolino A, Nawroz S, Matty VS, Barnett AS, Duyn JH, Moonen CTW, Frank JA, Tedeschi G, Weinberger DR . (1996): Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 153: 1554–1563
Blü S, Tan J, Adatia N, Karme A, Sproull T, Harris K, Ross BD . (1998): Cerebral Glycerophosphorylcholine and Ethanolamine Concentrations Are Elevated in Young Schizophrenics (abstract). Proceedings of the 6th Annual Scientific Meeting (Sydney) SMR, p 736
Deicken RF, Merrin EL, Floyd TC, Weiner MW . (1995): Correlation between left frontal phospholipids and Wisconsin Card Sorting Test performance in schizophrenia. Schizophr Res 14: 177–181
Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW . (1998): Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry 43: 483–488
Egan MF, Weinberger DR . (1997): Neurobiology of schizophrenia. Curr Opin Neurobiol 7: 701–707
Farooqui AA, Hirashima Y, Horrocks LA . (1992): Brain phospholipases and their role in signal transduction. In Bazan N.G. Murphy M.G. Tofano G(eds), Neurobiology of Essential Fatty Acids. New York, Plenum Press, 11–26
Fukuzako H, Fukuzako T, Takeuchi K, Ohbo Y, Ueyama K, Takigawa M, Fujimoto T . (1996): Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Prog Neuro-Psychopharmacol Biol Psychiatry 20: 629–640
Gattaz WF, Kollisch M, Thurn T, Virtanen JA, Kinnunen PKJ . (1987): Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol Psychiatry 22: 421–426
Gattaz WF, Schmitt A, Maras A . (1995): Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16: 1–6
Horrobin DF . (1998): The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30: 193–208
Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM . (1993): Three clinical syndromes of schizophreniain untreated subjects: Relation to brain glucose activity measured by positron emission tomography. Schizophr Res 11: 47–54
Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW . (1994): Changes in caudate volume with neuroleptic treatment. Lancet 344: 1434
Keshavan MS, Pettegrew JW, Panchalingam K . (1995): MRS in the study of psychoses: Psychopharmacological studies. In Nasrallah H.A. Pettegrew J.W(eds), NMR Spectroscopy in Psychiatric Brain Disorders. Washington DC, American Psychiatric Press, pp 131–146
Kilby PM, Allis JL, Radda GK . (1990): Spin-spin relaxation of the phosphodiester resonance in the 31P NMR spectrum of human brain: The determination of the concentrations of phosphodiester components. FEBS Lett 272: 163–165
Kitamura T, Yuzuriha T, Morita M, Itoh J, Suga R, Nakagawa Y . (1990): Oxford version of the BPRS: Development and validation of subscales. Psychiatric Diag 1: 101–107
Klemm E, Danos P, Grünwald F, Kasper S, Möller H-J, Biersack H-J . (1996): Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression—a study with single photon emission computed tomography. Psychiatry Res Neuroimag 68: 1–10
Kolakowska T . (1976): Brief Psychiatric Rating Scale: Glossaries and Rating Instructions. Oxford, Oxford University
Lawrie SM, Abukmeil SS . (1998): Brain abnormality in schizophrenia: A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 172: 110–120
Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ . (1992): Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160: 179–186
Maier M . (1995): In vivo magnetic resonance spectroscopy: Applications in psychiatry. Br J Psychiatry 167: 299–306
Matsuda H, Jibiki I, Kinuya S, Shuke N, Sumiya H, Tonami N, Hisada K . (1991): Tc-99m HMPAO SPECT analysis of neuroleptic effects on regional brain function. Clin Nucl Med 16: 660–664
McClure RJ, Keshavan MS, Pettegrew JW . (1998): Chemical and physiologic brain imaging in schizophrenia. Psychiatric Clin North Am 21: 93–122
McNamara R, Arias-Mendoza F, Brown TR . (1994): Investigation of broad resonances in 31P NMR spectra of the human brain in vivo. NMR Biomed 7: 237–242
Miller DD, Rezai K, Alliger R, Andreasen NC . (1997): The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: Assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography. Biol Psychiatry 41: 550–559
Murphy EJ, Rajagopalan B, Brindle KM, Radda GK . (1989): Phospholipid bilayer contribution to 31P NMR spectrum in vivo. Magn Reson Med 12: 282–289
Nilsson A, Risberg J, Johnason M, Gustafson L . (1977): Regional changes of cerebral blood flow during haloperidol therapy in patients with paranoid symptoms. Acta Neurol Scand 64(suppl):478–479
Nordahl TE, Kusubov N, Carter C, Salamat S, Cummings AM, O'Shora-Celaya L, Eberling J, Robertson L, Huesman RH, Jagust W, Budinger TF . (1996): Temporal lobe metabolic differences in medication-free outpatients with schizophrenia via the PET-600. Neuropsychopharmacology 15: 541–554
Oldfield RC . (1971): The assessment and analysis of handedness: The Edinburgh Inventory. Neuropsychologia 9: 97–113
Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, Allen M . (1991): Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics: A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48: 563–568
Potwarka J, Drost DJ, Williamson PC . (1996): A study of schizophrenia using 2D 31P chemical shift imaging with 1H decoupling (abstract). Proceedings of the 4th Annual Scientific Meeting (New York) SMR, p 998
Puri BK, Richardson AJ . (1998): Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentanoic acid. Arch Gen Psychiatry 55: 188–189
Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ . (1997): Increased phospholipid breakdown in schizophrenia: Evidence for the involvement of a calcium-independent phospholipase A2 . Arch Gen Psychiatry 54: 487–494
Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U . (1997): Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 349: 1735–1739
Schachter SC, Ransil BJ, Geschwind N . (1987): Associations of handedness with hair color and learning disabilities. Neuropsychologia 25: 269–276
Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S . (1994): Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res Neuroimag 55: 223–235
Singh SP, Shankar R . (1996): Effect of haloperidol on phospholipid biosynthesis in rat brain. Ind J Exp Biol 34: 111–114
Stanley JA, Panchalingam K, Miller G, McClure RJ, Pettergrew JW . (1997): A new method to quantify the broad component under the phosphodiester resonance and its application to study first-episode never medicated schizophrenics (abstract). Proceedings of the 5th Annual Scientific Meeting (Vancouver) SMR, p 1408
Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, Thompson RT . (1995): An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 52: 399–406
Williamson PC, Braner M, Leonard S, Thompson T, Drost D . (1996): 31P magnetic resonance spectroscopy studies in schizophrenia. Prostagland Leukot Essent Fatty Acids 55: 115–118
Zipursky RB, Zhang-Wong J, Lambe EK, Bean G, Beiser M . (1998): MRI correlates of treatment response in first episode psychosis. Schizophr Res 30: 81–90
Acknowledgements
This study was partially supported by grants from the Ministry of Science, Culture, and Education (05770735 and 06770764) and the National Center of Psychiatry and Neurology of the Ministry of Health and Welfare (3A-5) of Japan (Dr. H. Fukuzako).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fukuzako, H., Fukuzako, T., Kodama, S. et al. Haloperidol Improves Membrane Phospholipid Abnormalities in Temporal Lobes of Schizophrenic Patients. Neuropsychopharmacol 21, 542–549 (1999). https://doi.org/10.1016/S0893-133X(99)00050-0
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00050-0
Keywords
This article is cited by
-
Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target
Translational Psychiatry (2022)
-
Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations
Translational Psychiatry (2016)
